| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/13/2002 | CA2436856A1 Immunomodulatory constructs and their uses |
| 06/13/2002 | CA2436671A1 Rationally designed antibodies |
| 06/13/2002 | CA2431203A1 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 06/13/2002 | CA2430771A1 Dehydrated antigen presenting cells usable for vaccination |
| 06/13/2002 | CA2430621A1 Vaccine composition containing transforming growth factor alpha |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430379A1 Endogenous retroviruses up-regulated in prostate cancer |
| 06/13/2002 | CA2429769A1 Methods of treatment involving human mda-7 |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2428382A1 Intestinal proteins |
| 06/13/2002 | CA2428092A1 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | CA2427820A1 Method of producing biospecific molecules by protein trans-splicing |
| 06/12/2002 | EP1213587A1 Particles having gelatin coatings of and processes for making same |
| 06/12/2002 | EP1213299A1 Immunogenic epitopes of human papilloma virus and uses thereof |
| 06/12/2002 | EP1213032A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 06/12/2002 | EP1213030A1 Method for producing biologicals in protein-free culture |
| 06/12/2002 | EP1213028A1 Hm1.24 antigen expression potentiators |
| 06/12/2002 | EP1213020A2 Pharmaceutical compositions having appetite suppressant activity |
| 06/12/2002 | EP1212464A2 Diagnostics and therapeutics for osteoporosis |
| 06/12/2002 | EP1212446A2 Viral replicons and viruses dependent on inducing agents |
| 06/12/2002 | EP1212427A2 Basb128 polypeptide and polynucleotide fron moraxella catarrhalis |
| 06/12/2002 | EP1212426A1 Moraxella catarrhalis antigen, corresponding gene and uses thereof |
| 06/12/2002 | EP1212424A2 Moraxella catarrhalis antigen basb125 |
| 06/12/2002 | EP1212423A2 Identification of the domain of plasmodium falciparum erythrocyte membrane protein 1 (pfemp1) that mediates adhesion to chondroitin sulfate a |
| 06/12/2002 | EP1212422A2 Human ctla-4 antibodies and their uses |
| 06/12/2002 | EP1212421A1 Gas1 polypeptides |
| 06/12/2002 | EP1212417A2 Interleukin-1-receptor associated kinase-3 (irak3) |
| 06/12/2002 | EP1212415A1 Pgrp-l polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212407A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212363A2 Il-16 antagonists |
| 06/12/2002 | EP1212362A2 Card proteins involved in cell death regulation |
| 06/12/2002 | EP1212359A1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein |
| 06/12/2002 | EP1212358A2 Synthetic papillomavirus genes optimized for expression in human cells |
| 06/12/2002 | EP1212355A2 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 06/12/2002 | EP1212349A1 Recombinant subunit vaccine |
| 06/12/2002 | EP1212340A1 29 human cancer associated proteins |
| 06/12/2002 | EP1212334A1 Oligosaccharides derived from ribose-ribitol-phosphate, and vaccines containing them |
| 06/12/2002 | EP1212100A2 Delivery system for antidandruff agent |
| 06/12/2002 | EP1212088A1 Method for treatment of symptoms of central nervous system disorders |
| 06/12/2002 | EP1212087A1 Methods and compositions utilizing rad51 |
| 06/12/2002 | EP1212086A1 Immunological tolerance-induction agent |
| 06/12/2002 | EP1212085A2 Compositions for stimulating cytokine secretion and inducing an immune response |
| 06/12/2002 | EP1212084A2 Method of separating rotavirus variants and live attenuated rotavirus vaccine |
| 06/12/2002 | EP1212083A1 Oral recombinant lactobacilli vaccines |
| 06/12/2002 | EP1212082A1 Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies |
| 06/12/2002 | EP1212074A1 Hybrid peptides modulate the immune response |
| 06/12/2002 | EP1212066A1 Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids |
| 06/12/2002 | EP1212057A1 Extended duration light activated cancer therapy |
| 06/12/2002 | EP1212045A1 A vaccine composition and method of using the same |
| 06/12/2002 | EP1212043A2 Composition to be administered through mucous membrane |
| 06/12/2002 | EP0939655B1 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 06/12/2002 | EP0914416B1 Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors |
| 06/12/2002 | EP0873362B1 PROCESS FOR ISOLATING IgG AND IgA |
| 06/12/2002 | EP0822941B1 Monoclonal antibodies against hiv-1 and vaccines made thereof |
| 06/12/2002 | EP0817864B1 Method for the diagnosis of crohn's disease and ulcerative colitis |
| 06/12/2002 | EP0749325B1 Bispecific molecules having clinical utilities |
| 06/12/2002 | EP0678035B1 Vaccine preparations |
| 06/12/2002 | EP0574395B1 Cytokine immunoconjugates |
| 06/12/2002 | EP0433372B1 Oral immunization by transgenic plants |
| 06/12/2002 | CN1353615A Compositions of A-beta peptide and processes for producing same |
| 06/12/2002 | CN1353573A Anti-inflammatory therapy for inflammatory mediated infection |
| 06/12/2002 | CN1353185A Recombinant adenovirus of bone morphogenetic protein and its method for exciting bone generation |
| 06/12/2002 | CN1353114A Human papillomavirus 11L1-E7 recombination protein and its application |
| 06/11/2002 | USRE37741 Purified nontypable Haemophilus influenzae P5 protein as a vaccine for nontypable Haemophilus influenzae infection |
| 06/11/2002 | US6404779 System and method of disharmonic frequency multiplexing |
| 06/11/2002 | US6403769 Fusion protein having nonantibody portion comprised of effector domain from growth factor or growth factor receptor joined to aminoterminal end of immunoglobulin g-derived sequence which lacks ch1 domain |
| 06/11/2002 | US6403630 Administering a cyclooxygenase-2 (cox-2) inhibitor alone or in combination with herceptin? antibody; used to treat breast cancer |
| 06/11/2002 | US6403559 C-kit ligand-based method for expanding peripheral blood cell levels |
| 06/11/2002 | US6403552 Ob receptor and methods for the diagnosis and treatment of body weight disorders |
| 06/11/2002 | US6403363 Method of preservation of vaccines with polybiguanide |
| 06/11/2002 | US6403337 Staphylococcus aureus genes and polypeptides |
| 06/11/2002 | US6403334 gidB from Staphylococcus aureus |
| 06/11/2002 | US6403308 Methods for detecting and reversing resistance to macrocyclic lactone compounds |
| 06/11/2002 | US6403306 Detection and diagnosis of meningococcal strains; vaccines with capsular polysaccharide conjugates; genetic engineering |
| 06/11/2002 | US6403117 Archaesomes, archaeosomes containing coenzyme Q10 and other types of liposomes containing coenzyme Q10 adjuvants and as delivery vehicles |
| 06/11/2002 | US6403104 Hapten-conjugated mammalian cells and methods of making and using thereof |
| 06/11/2002 | US6403103 Cytoplasmic protein fragment selected from: the amino acid sequence from residue 402 to residue 426 of seq id no: 2; and an immunogenic fragment of said amino acid sequence comprising at least residue 408 to residue 417 of said amino acid |
| 06/11/2002 | US6403102 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 06/11/2002 | US6403101 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 06/11/2002 | US6403100 Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated |
| 06/11/2002 | US6403099 Conjugates formed from heat shock proteins and oligo-or polysaccharides |
| 06/11/2002 | US6403098 Buffer, sugar, phosphate, recombinant human serum albumin, polysorbate |
| 06/11/2002 | US6403097 Deletion in the glycoprotein ge-gene |
| 06/11/2002 | US6403095 Treatment of primary and metastatic neoplastic diseases with HSP70-peptide complexes |
| 06/11/2002 | US6403094 Clostridium perfringens vaccines |
| 06/11/2002 | US6403093 Methods to detect granulocytic ehrlichiosis |
| 06/11/2002 | US6403091 Produced by the hybridoma having atcc accession no. hb 10916. |
| 06/11/2002 | US6403090 Peptides which mimic candida carbohydrate epitopes and their use in a vaccine |
| 06/11/2002 | US6403089 Inhibitors of fgl2; bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, gastrointestinal diseases and fetal loss; monoclonal and polyclonal antibodies which bind to fgl2 and prevent fibrin |
| 06/11/2002 | US6403087 Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of immunological disease |
| 06/11/2002 | US6403081 Generating immunology response |
| 06/11/2002 | US6403080 Methods of modulating an immune response to antigen, and cells for use in the method |
| 06/11/2002 | US6403077 Treatment regimes featuring an IL-10-containing chimeric polypeptide |
| 06/11/2002 | CA2152266C Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/turyosinase peptide antigens |
| 06/11/2002 | CA2124218C Cytotoxic drug therapy |
| 06/11/2002 | CA2088478C Cloning and expression of a rhoptry associated protein of p. falciparum |
| 06/11/2002 | CA2082390C Dna encoding human 5-ht1d receptors and uses thereof |
| 06/06/2002 | WO2002044734A1 Method for diagnosing a tumor in a patient determining the concentration of pibf |
| 06/06/2002 | WO2002044718A2 S.aureus protein staau r2, gene encoding it and uses thereof |
| 06/06/2002 | WO2002044419A2 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |